NCT02218060

Brief Summary

Coronary CT angiography is used to examine the coronary arteries in a non-invasive way when a patient is suspected of having coronary artery disease. The test, however, requires relatively high levels of radiation, which have been linked to DNA damage and cancer, and the use of contrast material, which can affect kidney function. The SOMATOM Force, a new third-generation CT scanner manufactured by Siemens, was recently installed at MUSC and holds the potential to obtain quality images while also reducing radiation dose and contrast material. This study aims to test the diagnostic ability of the SOMATOM Force in detecting coronary artery disease and also see if radiation dose and contrast material are reduced compared to the previous 2nd generation scanners. It is suspected that the Force will provide clinical quality images while decreasing radiation dose and contrast material required.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at below P25 for not_applicable coronary-artery-disease

Timeline
Completed

Started Jan 2014

Typical duration for not_applicable coronary-artery-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 14, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 15, 2014

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2017

Completed
Last Updated

May 2, 2018

Status Verified

April 1, 2018

Enrollment Period

3.8 years

First QC Date

August 14, 2014

Last Update Submit

April 30, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Radiation dose and contrast material

    To determine the potential for reductions in radiation dose and contrast material requirements by performing coronary CT angiography at low tube potential with the new CT system.

    one year

Secondary Outcomes (1)

  • Diagnostic accuracy

    one year

Study Arms (2)

Force

EXPERIMENTAL

Patients receiving coronary CT angiography on the SOMATOM Force before clinically indicated cardiac catheterization or after clinically indicated nuclear stress test

Procedure: Coronary CT angiography on SOMATOM Force

Control

OTHER

Patients who have already received comparable CT examinations on current routine 2nd generation dual-source CT systems

Procedure: Previous coronary CT angiography on 2nd generation CT scanner

Interventions

Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis

Force

Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner

Control

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject must be between 18-90 years of age.
  • Subject must have been referred for a clinically indicated cardiac catheterization or nuclear cardiac perfusion study.
  • Subject must provide written informed consent prior to any study-related procedures being performed.
  • Subject must be willing to comply with all clinical study procedures.

You may not qualify if:

  • Subject is a pregnant or nursing female. Exclude the possibility of pregnancy:
  • By testing (urine βHCG) within 24 hours before contrast agent administration, or
  • By surgical sterilization, or
  • Post menopausal, with minimum one (1) year history without menses.
  • Subject has an acute psychiatric disorder or is cognitively impaired.
  • Subject is using or is dependent on substances of abuse.
  • Subject is unwilling to comply with the requirements of the protocol.
  • Subject has decreased renal function (eGFR \<45)
  • Subject has an allergy against iodinated contrast agents.
  • Subject is in acute unstable condition.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MUSC Ashley River Tower

Charleston, South Carolina, 29401, United States

Location

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • U. Joseph Schoepf, MD

    Medical University of South Carolina

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 14, 2014

First Posted

August 15, 2014

Study Start

January 1, 2014

Primary Completion

November 1, 2017

Study Completion

November 1, 2017

Last Updated

May 2, 2018

Record last verified: 2018-04

Locations